To explore whether MKK3 depletion might impact on tumor cell response to anticancer drugs, we demonstrated that MKK3 knockdown improves response to therapies, in both wtp53 and mutp53 cancer cells, allowing chemotherapeutic dose reduction. The gene discussed is MAP2K3; the disease is cancer.